Patrick J Stiff
Overview
Explore the profile of Patrick J Stiff including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
84
Citations
4909
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Stiff P, Kertowidjojo E, Potkul R, Banerjee S, Mehrotra S, Small Jr W, et al.
Am J Cancer Res
. 2024 Nov;
14(10):4788-4802.
PMID: 39553221
Ovarian cancer is usually detected in the advanced stages. Existing treatments for high grade serous ovarian cancer (HGSOC) are not adequate and approximately fifty percent of patients succumb to this...
2.
Wang S, Scurti G, Dalheim A, Quinn S, Stiff P, Nishimura M
Blood Adv
. 2023 Nov;
8(2):324-335.
PMID: 37967375
CD19-specific chimeric antigen receptor (CAR) T cells have demonstrated impressive responses in patients with relapsed and refractory B cell malignancies. However, many patients relapse or fail to respond to CD19...
3.
Stiff P, Mehrotra S, Potkul R, Banerjee S, Walker C, Drakes M
Cancers (Basel)
. 2023 Sep;
15(18).
PMID: 37760508
Background: High-grade serous ovarian cancer is a lethal gynecologic disease. Conventional therapies, such as platinum-based chemotherapy, are rendered inadequate for disease management as most advanced disease patients develop resistance to...
4.
Shah B, Cassaday R, Park J, Houot R, Oluwole O, Logan A, et al.
J Immunother Cancer
. 2023 Aug;
11(8).
PMID: 37648261
Background: Brexucabtagene autoleucel (brexu-cel) is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy approved in the USA for adults with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL)...
5.
Lin C, Sajeev G, Stiff P, Brunstein C, Cutler C, Sanz G, et al.
Transplant Cell Ther
. 2022 Sep;
29(1):52.e1-52.e9.
PMID: 36179986
Omidubicel is an advanced cell therapy derived from umbilical cord blood (UCB) for use in allogeneic hematopoietic cell transplantation (HCT). A recent randomized phase 3 clinical trial demonstrated faster engraftment,...
6.
Riedell P, Hamadani M, Ahn K, Litovich C, Brunstein C, Cashen A, et al.
Br J Haematol
. 2021 Sep;
195(5):757-763.
PMID: 34581433
In young and fit patients with mantle cell lymphoma (MCL), intensive induction therapy followed by a consolidative autologous haematopoietic cell transplant (autoHCT) is the standard of care in the front-line...
7.
Riedell P, Hamadani M, Ahn K, Litovich C, Guru Murthy G, Locke F, et al.
Transplant Cell Ther
. 2021 Aug;
27(11):911.e1-911.e7.
PMID: 34450333
Although autologous hematopoietic cell transplantation (auto-HCT) has become a common practice for eligible patients in the front-line setting with mantle cell lymphoma (MCL), there are limited data regarding trends in...
8.
Drakes M, Stiff P
Adv Exp Med Biol
. 2021 Aug;
1330:33-54.
PMID: 34339029
Ovarian cancer generally escapes diagnosis until the advanced stages. High-grade serous ovarian cancer (HGSOC) is the most frequently occurring form of this malaise and is a disease which has the...
9.
Lazaryan A, Dolan M, Zhang M, Wang H, Kharfan-Dabaja M, Marks D, et al.
Haematologica
. 2021 Aug;
106(8):2295-2296.
PMID: 34333962
No abstract available.
10.
de Koning C, Tao W, Lacna A, van Veghel K, Horwitz M, Sanz G, et al.
Bone Marrow Transplant
. 2021 Jul;
56(11):2826-2833.
PMID: 34312498
Omidubicel (nicotinamide-expanded cord blood) is a potential alternative source for allogeneic hematopoietic cell transplantation (HCT) when an HLA-identical donor is lacking. A phase I/II trial with standalone omidubicel HCT showed...